Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This Phase Ib trial evaluates the efficacy and safety of finotonlimab, a PD‐1 antibody, combined with SCT200, an EGFR antibody, combined with SCT200.